Overview

Safety and Tolerability of 4975 in the Treatment of Moderate to Severe Knee Pain Due to Osteoarthritis (OA)

Status:
Completed
Trial end date:
2016-08-01
Target enrollment:
Participant gender:
Summary
This study will evaluate dosing regimens of 4975 in terms of safety and tolerability when delivered as an intra-articular injection in the knee. Secondary objectives will be to explore the efficacy of 4975 in terms of onset, extent and duration of pain relief.
Phase:
Phase 2
Details
Lead Sponsor:
Centrexion Therapeutics